Budesonide modulite®: Improving the changeover to CFC-free treatments

Respiratory Medicine

Volumn 97, Issue SUPPL. D, 2003, Pages

  Magnussen, H ^a  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE MODULITE; CHLOROFLUOROCARBON; CHOLINERGIC RECEPTOR BLOCKING AGENT; CICLESONIDE; CORTICOSTEROID; FLUORINATED HYDROCARBON; MOMETASONE FUROATE; NORFLURANE; PROPELLANT; SALBUTAMOL; BRONCHODILATING AGENT;

AEROSOL; ASTHMA; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; DRY POWDER; EDITORIAL; HUMAN; LUNG FUNCTION TEST; METERED DOSE INHALER; NEBULIZER; PHYSICAL CHEMISTRY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBLEM SOLVING; SIDE EFFECT; ARTICLE;

AEROSOL PROPELLANTS; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CHLOROFLUOROCARBONS; HUMANS; NEBULIZERS AND VAPORIZERS;

EID: 2342612835     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2003.10.002     Document Type: Article

References (11)

1. NHLBI/WHO Workshop Report: Global Strategy for Asthma Management and Prevention 1995 (update 2002) NIH Publication No 02-3659.
2. Sakula A. A history of asthma. J Roy Coll Phys Lond 1988;22: 36-44.
3. Montreal Protocol on substances that deplete the ozone layer, Final Act (Nairobi: UNEP, 1987). Federal Register 1994; 59: 56276-98.
4. Strategy for the phase out of CFCs in metered dose inhalers, Commission of the European Communities, 23:10:1998, COM (1998) 603 final.
5. Brambilla G, Ganderton D, Garzia R, Lewis D, Meakin B, Ventura P. Modulation of aerosol clouds produced by pressuried inhalation aerosol. Int J Pharm 1999;186:53.
6. Holz, Jorres RA, Magnussen H. Monitoring central and peripheral airway inflammation in asthma. Respir Med 2000; 94(Suppt D):S7-12.
7. Wohlsen A, Martin C, Vollmer E, Branscheid D, Magnussen H, Becker WM, Lepp U, Uhlig S. The early allergic response in small airways of human precision-cut lung slices. Eur Respir J 2003;21:1024-32.
8. Goldin JG, McNitt-Gray MF, Sorenson SM, Johnson TD, Dauphinee B, Kleerup EC, Tashkin DP, Aberle DR. Airway hyperreactivity: assessment with helical thin-section CT. Radiology 1998;208:321-9.
9. Ganderton D. Lewis D, Davies R, Meakin B, Church T. The formulation and evaluation of a CFC-free budesonide pressurised metered dose inhaler. Respir Med 2003; 97(Suppl.D):S4-9.
10. Grzelewska-Rzymowska I, Malolepszy J, de Molina M, Sladek K, Zarkovic J, Siergiejko Z. Equivalent asthma control and systemic safety of inhaled budesonide delivered via HFA-134a or CFC propellant in a broad range of doses. Respir Med 2003;97(Supp.D):S10-9.
11. Vastagh E, Kuna P, Calistru P, Bogdan MA. Efficacy and safety of inhaled budesonide delivered once or twice daily via HFA-134a in mild to moderate persistent asthma in adult patients. Comparison with Budesonide CFC. Respir Med 2003;97(Suppl.D):S20-8.